Critical Updates in Pediatrics, Part 2: CHF, Cystic Fibrosis, and Traumatic Brain Injury

Tuesday, December 4, 2012
3:30 pm – 5:00 pm

Planned in cooperation with the ASHP Section of Clinical Specialists and Scientists
Activity #: 204-000-12-297-L01P
Level of Content: Advanced
1.50 Contact Hours / Knowledge-based
Program Chair: Elizabeth Anne Farrington, PharmD, BCPS

Learning Objectives:

• Explain the current guidelines for infants and children with cystic fibrosis.
• Evaluate the current literature regarding the efficacy and safety of VX-770 (KalydecoTM) in combination with VX-809 a new agent-in-development, for the treatment of cystic fibrosis.
• Describe the pathophysiology and treatment of pediatric heart failure and how it differs from adult heart failure.
• Describe the causes of traumatic brain injury (TBI) based on the age of the patient and how this changes empiric testing or medication management.
• Review the new SCCM pediatric TBI guideline and application of key changes to the treatment of the pediatric patient.